Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore (NASDAQ:ECOR) has secured a significant regulatory milestone as its gammaCore™ Sapphire (nVNS) device received reimbursement approval from Belgium's National Institute for Health and Disability Insurance (RIZIV/INAMI). The coverage, effective October 1, 2025, will provide Belgian patients suffering from cluster headaches access to this bioelectronic treatment.
The approval was achieved through collaboration with Silvert Medical, electroCore's distribution partner in Belgium, and is supported by strong clinical evidence demonstrating the therapy's efficacy and cost-effectiveness. Prof. Paemeleire from Ghent University Hospital's Headache Clinic endorsed the decision, highlighting the benefits of non-invasive vagus nerve stimulation for patients.
[ "Secured reimbursement approval in Belgium, expanding market access", "Partnership with established distributor Silvert Medical for market penetration", "Strong clinical evidence supporting therapy efficacy and cost-effectiveness", "Strategic position in central Europe for potential expansion to neighboring countries" ]electroCore (Nasdaq: ECOR) announced that its Truvaga™ Plus device has been awarded "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards. The handheld vagus nerve stimulation (nVNS) device was selected by Esquire's editors after extensive testing, recognized for its ability to promote relaxation and better sleep through two-minute sessions.
The device stands out for its drug-free approach to calming the nervous system, reducing stress, and enhancing sleep quality. This recognition in Esquire's annual Sleep Awards, which highlights the most effective sleep and recovery solutions, serves as third-party validation for consumers seeking alternative sleep improvement methods.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Andy Brown as VP, Corporate Controller effective September 9, 2025. As part of his employment package, Brown was granted 10,000 restricted stock units (RSUs) as an inducement award under NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest in three equal installments of 33% each on the first, second, and third anniversaries of the grant date, contingent upon Brown's continued employment. Upon vesting, the RSUs will be converted into shares of electroCore's common stock.
[]electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced leadership changes in its Board of Directors. Peter Cuneo is departing from the Board but will continue as a strategic advisor, while Dr. Thomas J. Errico has been elected as the new Chairman of the Board, effective September 2, 2025.
Cuneo served as a Board member since 2020 and as Chairman since 2021, playing a crucial role in electroCore's turnaround. Dr. Errico, who co-founded electroCore and previously served as Chairman of the Nominating and Governance Committee, will now lead the Board with his extensive experience in the company.
electroCore (NASDAQ: ECOR) has announced a partnership with former New York Jets linebacker Greg Buttle to promote Truvaga™ Plus, their next-generation vagus nerve stimulation (nVNS) device. The partnership aims to raise awareness about the device's benefits for sleep improvement and stress relief.
Truvaga is a portable wellness device that stimulates the vagus nerve in two-minute sessions, helping users achieve better sleep and relaxation without medication. The partnership includes radio spots and digital campaigns, leveraging Buttle's NFL experience and broadcasting background to showcase how Truvaga supports stress management and sleep quality.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Elena Bonfiglioli to its Board of Directors, effective September 2, 2025. Bonfiglioli, who currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and International clinical applications' solutions, brings over two decades of healthcare sector experience.
Bonfiglioli, recognized as one of the top 50 AI Innovators by Intelligent Health, replaces Peter Cuneo on the board. She currently serves on the Drug Information Association Regional Advisory Council and holds board positions at several European and Middle Eastern startups. Her expertise spans AI transformation initiatives in healthcare, data utilization for research, and longevity sector innovations.
electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held on September 9, 2025, at the Lotte New York Palace Hotel in New York.
The company's management team will be available for one-on-one meetings throughout the conference day. Interested investors can schedule meetings through their H.C. Wainwright sales representative or by contacting electroCore's Investor Relations directly.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Kelly Benning as Senior Vice President of Truvaga, effective July 21, 2025. Benning brings nearly 30 years of leadership experience in digital health, AI technologies, and consumer wellness.
Benning's impressive background includes pioneering the first FDA-cleared blood pressure monitoring watch and holding executive positions at LiveMetric, IBM Watson Health, CipherHealth, and other healthcare companies. In her new role, she will lead electroCore's consumer wellness division, focusing on strategic partnerships and expanding access to consumer devices through the company's digital wellness platform, Truvaga.
[ "Appointment of experienced executive with nearly 30 years in digital health and AI technologies", "Strategic focus on expanding direct-to-consumer market access", "Addition of leader with proven track record in FDA-cleared medical device commercialization" ]electroCore (NASDAQ: ECOR) reported strong Q2 2025 financial results with record revenue of $7.4 million, representing a 20% year-over-year increase. The company's year-to-date revenue reached $14.1 million, up 22% compared to the first half of 2024.
Key financial metrics include gross profit of $6.4 million with an 87% margin, though operating expenses increased to $9.9 million. The company reported a GAAP net loss of $3.7 million ($0.44 per share). Cash position stood at $7.4 million as of June 30, 2025, supplemented by a recent $7.2 million term debt facility.
electroCore projects full-year 2025 revenue of approximately $30.0 million with expected net cash usage between $3.9-$4.4 million for the remainder of the year. The company successfully completed the NeuroMetrix acquisition ahead of schedule.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has appointed James C. Theofilos to its Board of Directors, effective August 1, 2025.
Theofilos currently serves as Senior Finance Manager in Microsoft's Azure and AI division, leading finance for the AI Apps & Agents team. His experience includes roles as Finance Lead for Microsoft's Global Healthcare & Life Sciences Sales team and as Group Project Manager at VICI Properties. The Theofilos family has been an early investor and founding partner of electroCore, demonstrating long-term commitment to the company's vision in vagus nerve technology.